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FDA was created in 1906 as one of our nation’s 
principal consumer product protection agencies 
and is now responsible for assuring the safety of 
biologics, such as blood products and vaccines, 
drugs, medical devices, foods, cosmetics, and 
many other consumer goods. Since 2009, it 
has also been responsible for regulating the 
manufacture, marketing, and distribution of 
tobacco products. In the U.S., FDA-regulated 
products account for about 25 cents of every 
dollar spent by American consumers each 
year —products that touch the lives of every 
American every day. FDA is responsible for 
advancing the public health by helping to speed 
innovations that make foods safer and make 
medicines and devices safer and more effective. 
At the same time, FDA helps consumers and 
health care providers get the accurate and 
science-based information they need to make 
the best possible decisions about their use of 
medical products and foods for human and 
non-human animal use. FDA must make 
decisions based on the best available scientific 
data and using the best tools and methods 
available in order to ensure products meet 
the highest quality standards for consumers, 
while at the same time fostering and advancing 
innovation in the products it regulates.
The core responsibility of FDA is to protect 
consumers by applying the best possible science 
to its regulatory activities—from pre-market 
review of efficacy and safety to post-market 
product surveillance to review of product 
quality. In the last few years, rapid advances 
in innovative science have provided new 
technologies to discover, manufacture and 
assess novel medical products, and to improve 
food safety and quality; FDA must both keep 
pace with and utilize these new scientific 
advances in order to accomplish its mission to 
protect and promote the health of our nation.
FDA’s Strategic Plan for 
Regulatory Science 
To meet this need, FDA has developed a 
strategic plan for regulatory science, the 
Executive Summary
T
he Food and Drug 
Administration (FDA) 
protects and promotes 
the health and safety of 
all Americans through 
enhancing the availability of 
safe medical products and foods 
and promoting innovation that 
addresses unmet medical and public 
health needs. FDA also protects 
and promotes the health and safety 
of animals through assuring the 
availability of safe animal drug 
products and food. FDA is a science-
based regulatory agency, and a 
critical component to the success 
of the nation’s public health, health 
care systems, and economy.
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science of developing new tools, standards, 
and approaches to assess the safety, efficacy, 
quality, and performance of FDA-regulated 
products. This plan identifies eight priority 
areas of regulatory science where new or 
enhanced engagement is essential to the 
continued success of FDA’s public health and 
regulatory mission. The priority areas are:
1.  Modernize Toxicology to Enhance 
Product Safety
2.  Stimulate Innovation in Clinical Evaluations 
and Personalized Medicine to Improve 
Product Development and Patient Outcomes
3.  Support New Approaches to Improve 
Product Manufacturing and Quality
4.  Ensure FDA Readiness to Evaluate 
Innovative Emerging Technologies
5.  Harness Diverse Data through Information 
Sciences to Improve Health Outcomes
6.  Implement a New Prevention-Focused Food 
Safety System to Protect Public Health
7.  Facilitate Development of Medical 
Countermeasures to Protect Against Threats 
to U.S. and Global Health and Security
8.  Strengthen Social and Behavioral Science 
to Help Consumers and Professionals 
Make Informed Decisions about Regulated 
Products 
FDA will apply available resources to 
implement the Strategic Plan for Regulatory 
Science through management of scientific 
programs within FDA and engagement 
of collaborators and partners in industry, 
academia and government. FDA’s Strategic 
Plan for Regulatory Science is designed to 
allow the Agency both to meet today’s public 
and animal health needs and to be fully 
prepared for the challenges and opportunities 
of tomorrow to help harness revolutions in 
science that can be translated into products 
that help make and keep our nation both safe 
and healthy. 
FDA’s strategic plan is designed to allow the 
Agency both to meet today’s public health needs 
and to be fully prepared for the challenges and 
opportunities of tomorrow.
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Introduction
The complexity of FDA‘s regulatory and public 
health portfolio is growing rapidly, in large 
part due to scientific challenges inherent in 
evaluating a new generation of products based 
on quickly evolving science and technology. 
Layered on this are the realities of an expanding 
global economy that requires FDA to evaluate 
and manage risks associated with a vast array 
and volume of regulatory data, products, and 
ingredients produced in a multitude of global 
locations. New drugs, biologics and medical 
devices are increasingly complex in their 
development, manufacture, and evaluation. 
Sophisticated global markets move foods 
from foreign farms to supermarkets with 
increasing speed. Finished products may 
contain a complicated array of ingredients and 
components, all sourced from shifting global 
commodities markets and often of uncertain 
provenance. The addition of tobacco products 
to FDA’s regulatory responsibilities poses new 
regulatory challenges in need of new scientific 
solutions to better protect the public from 
harm. In addition, improved information 
technology capacity provides opportunities 
to harness the substantial data resources both 
within and external to FDA for regulatory 
decision-making.
The challenges of modern product development 
and globalization underscore the critical 
importance of modernizing and advancing 
regulatory science to match advances in basic 
and applied science and technology. Clearly, for 
scientific advances to realize their full potential 
for improving public health, FDA must be able 
to issue clear guidance, play a major role in the 
improvement of modern product and process 
 F
DA is responsible for assuring the safety of foods, drugs, medical devices, 
biologics—such as vaccines, blood products, cell and gene therapy 
products, and tissues—cosmetics, and many other consumer goods, 
as well as foods and drugs for animals. Since 2009, it has also been 
responsible for regulating the manufacture, marketing, and distribution 
of tobacco products. FDA is also responsible for advancing the public health by 
helping to speed innovations that provide our nation with safe and effective 
medicines and devices and keep our food supply safe, while helping Americans get 
the accurate, science-based information they need to use medical products and 
consume foods to improve and maintain their health.
U. S .  Food and  D r ug  Admin i s t r a t ion  /  Ad v anc in g  Re gu l a t o r y  S c i en ce  a t  FDA 5
development tools, and make sound regulatory 
decisions about risks and benefits of products 
that increasingly involve new technologies.
 
To help meet these challenges, FDA has 
developed this Strategic Plan for Regulatory 
Science, the science of developing new tools, 
standards, and approaches to assess the 
safety, efficacy, quality, and performance of 
FDA-regulated products. This work builds 
upon the white paper Advancing Regulatory 
Science for Public Health1 and the FDA Strategic 
Priorities.2 In this work, FDA identifies priority 
areas where new or enhanced investments in 
regulatory science research capacity will be 
essential to continued mission success and to 
public health and safety. 
FDA will accomplish this plan by applying 
its knowledge base, laboratories, scientific 
computing capabilities, and expertise, while 
leveraging resources and collaborating with 
domestic and international partners in 
government and academia. Where appropriate, 
FDA will also engage stakeholders from the 
private sector in this effort. FDA will use 
this plan to ensure that its regulatory science 
programs focus on the identified priorities, in 
combination with Center-specific approaches, 
but will also revisit these priorities regularly 
and seek public input to address evolving 
challenges, opportunities and changes in the 
science and innovation landscape. 
1. Advancing Regulatory Science for Public Health accessible at:
http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RegulatoryScience/UCM228444.pdf
2. FDA Strategic Priorities accessible at: 
http://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/ucm227527.htm
FDA identifies priority 
areas where new or 
enhanced investments 
in regulatory science 
research capacity will 
be essential to mission 
success and to public 
health and safety. 
FDA will advance regulatory science to 
speed innovation, improve regulatory 
decision-making, and get safe and 
effective products to people in need. 
21st Century regulatory science will 
be a driving force as FDA works 
with diverse partners to protect and 
promote the health of our nation and 
the global community.
Vision
Statement
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Science Priority Areas
 F
DA has identified eight priority areas where new or enhanced engagement 
in regulatory science research is essential to advancing its regulatory 
mission. These priority areas are not restricted to one product area; 
rather, they address cross-cutting needs and opportunities that typically 
extend across several product areas where benefits and engagement from 
regulatory science successes will enhance product development, evaluation and 
health outcomes related to multiple products and populations. FDA’s strategic 
plan for regulatory science is critical to the continued success of the Agency in 
meeting its regulatory mission and facilitating the translation of breakthrough 
discoveries into innovative, safe and effective products of tomorrow.
Preclinical testing serves a fundamental role in 
characterizing the potential risks associated with 
new FDA-regulated products. However, serious 
and sometimes rare and unexpected adverse 
events may be observed in clinical trials or post-
approval, suggesting that critical gaps exist in 
our understanding of the relationship between 
patient response and preclinical toxicology 
findings. For example, non-clinical safety 
assessment is often conducted in normal healthy 
test systems and tends to be exposure-based; it 
does not attempt to evaluate the possible risk 
of rare or idiosyncratic responses that may arise 
from potential interactions with the presence or 
progression of disease or the genetic background 
or other exposures of patients and consumers. 
Also, in some cases, the true predictive accuracy 
of many toxicology models and safety assays 
remains uncertain and in need of more rigorous 
validation against actual human and animal 
adverse event data to define their reliability and 
possible limitations. For tobacco products, a 
deeper understanding of the negative effects of 
tobacco constituents and how best to measure 
and, wherever possible, reduce those effects 
is needed to assess public health impact.  
Finally, the introduction of new measurement 
technologies and increasing knowledge 
about toxicity mechanisms and pathways 
offer important opportunities for advanced 
computational analyses that can promote the 
effective translation of non-clinical findings to 
the clinical setting. FDA can close these gaps and 
improve preclinical safety predictions by further 
Modernize Toxicology to Enhance 
Product Safety1
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investing in three particular areas of regulatory 
science: the evaluation and development of 
models and assays that better predict patient 
response, the identification and evaluation 
of more reliable biomarkers for monitoring 
toxicities, side effects, and abnormalities, and the 
use of computational tools to integrate and draw 
conclusions from a wide range of preclinical 
safety data types and sources.
Implementation Strategy 
FDA will seek to improve the prediction of 
product safety and efficacy based on preclinical 
data by conducting internal and collaborative 
research to address the following needs:
1.  Develop better models of human adverse 
response: 
a)  Evaluate and promote the use of cell- and 
tissue-based assays that more accurately 
represent human susceptibility to adverse 
reactions;
b)  Modernize the development and use of 
animal models that consider the potential 
influence of disease progression and disease 
co-morbidities on the emergence of adverse 
events;
c)  Promote a better understanding of toxicity 
mechanisms by evaluating safety assessment 
data at multiple levels of biological 
organization, including genes, proteins, 
pathways, and cell/organ function;
d)  Assess and characterize molecular targets 
and host genetic factors that may be 
associated with rare and unexpected adverse 
events (“off-target” drug effects); and
e)  Initiate in vitro and in vivo studies to identify 
potential markers of harm associated with 
exposure to tobacco constituents
2.  Identify and evaluate biomarkers and 
endpoints that can be used in non-clinical 
and clinical evaluations:
a)  Evaluate the accuracy (specificity and 
sensitivity) with which animal models and 
cell-based assays correctly predict potential 
human risk;
b)  Assess concordance between animal and 
human markers of toxicity and determine 
how the performance of these markers 
and their interpretation may vary across 
different organ systems and human 
populations; and
c)  Evaluate quantitative imaging (e.g., positron 
New Models to Assess Safety 
of Gene Therapy
There are currently numerous clinical trials using a promising new class of cancer 
therapies based on adenovirus—a variation of a common cold virus that can be 
engineered to deliver cancer-killing gene therapies. However, rapid clearance of 
adenovirus by the liver prevents the virus from finding the target cancer cells 
and, in some cases, may cause liver toxicity. FDA scientists have developed animal 
models to study how the liver clears adenovirus from circulation and how adenovirus 
triggers toxic reactions. As a result, they have been able to identify methods to 
block receptors that the liver uses to clear adenovirus vectors from circulation. They 
have also identified adenovirus-induced mediators that could potentially be blocked 
to improve safety. For example, adenovirus injections in rats and mice rapidly induce  
a toxic mediator that can cause lethal shock. Scientists can block this mediator with 
a drug, completely protecting the animals from shock.
1
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emission tomography, magnetic resonance 
imaging, computed tomography) and other 
advanced approaches (e.g., metabolomics) 
for identifying new biomarkers and 
predictors of efficacy and safety.
3.  Use and develop computational methods and 
in silico modeling:
a)  Improve the use of chemical Structure-
Activity Relationship (SAR) models in the 
prediction of human risk and integrate this 
analysis into the review process;
b)  Develop and implement approaches to 
link chemical structures and substructures 
to a wide range of information about 
product safety, disease targets, and toxicity 
mechanisms;
c)  Develop clinical trial simulation models 
that can reveal interactions between drug or 
device effects, patient characteristics, and 
disease variables influencing outcomes;
d)  Develop computer models of cells, organs, 
and systems to better predict product safety 
and efficacy;
e)  Implement computer models that integrate 
pharmacokinetic, pharmacodynamic, 
materials science, or mechanistic safety data 
to predict clinical risk-benefit and confirm 
post-marketing safety in different patient 
populations; and
f)  Develop and apply data mining, knowledge 
building, and data visualization tools to 
inform computer model development, 
clinical risk prediction, and regulatory 
decision-making.
Public Health Impact
By addressing these needs, FDA will be better 
able to identify and accurately predict and 
reduce the magnitude and likelihood of 
risks associated with products. This, in turn, 
will help both speed and reduce costs in 
achieving the delivery of safe and effective 
new products to market, leading to improved 
health outcomes and reduced patient risk. By 
continuing to explore and integrate new tools 
and approaches in the evaluation of product 
safety, FDA will be better able to estimate 
dose ranges, help promote more informed 
device designs for safe use in clinical trials, 
and develop and use more sensitive and 
reliable ways to identify and confirm safety 
issues at earlier times during the medical 
product development process. FDA Centers 
will also be better able to anticipate the risk 
and nature of product-related adverse events 
and to understand the mechanisms by which 
these events occur in specific individuals or 
subpopulations. Modernizing toxicology and 
continually improving the ability of non-
clinical tests, models, and measurements to 
predict product safety issues will increase the 
likelihood that toxicity risks will be identified 
earlier in product development, assuring 
patient safety, and mitigating the need to 
withdraw previously approved products.
This will help speed the 
delivery of safe and 
effective new products 
to market, leading to 
improved health outcomes 
and reduced risk.
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Rapid identification of potential therapeutic 
targets for medical product development has 
been facilitated by widely accessible biological 
information, sophisticated bioinformatics 
tools to map pathways and build systems 
biology models, and high throughput 
screening methods. There has also been 
significant progress in understanding how 
genomic variations alter an individual’s 
response to activation or inhibition of these 
therapeutic targets, enabling potential 
improvements in the clinical use of existing 
therapeutics and opening up the possibility 
of co-developing therapies and tests that 
can be used to tailor treatment to individual 
patients (personalized medicine). Indeed, 
genomic information has already been added 
to drug labels to identify patients who will 
most benefit from a drug, identify patients 
who will be at most risk of an adverse drug 
reaction, and select the optimal dose for 
a given patient. Despite this progress, the 
process of translating new scientific findings 
into safe and effective use of medical products 
and optimizing the use of existing products 
for all populations remains a major challenge. 
Clinical development programs are lengthy 
and expensive with uncertain outcomes. There 
is an imperative to speed efficacious medical 
products to patients by increasing efforts to 
reduce the uncertainties in this process.
Clinical development programs for medical 
products (drugs, biologics, and devices 
intended to treat disease) are dependent on 
the availability of tools, such as endpoints 
predictive of efficacy and toxicity, as well as 
effective clinical trial design and analysis 
methods. Central to effective clinical 
evaluation is the availability of clinically 
meaningful measures. These often utilize 
analytical measurements which employ 
Companion Diagnostics
Recent biomedical breakthroughs are pushing medicine toward tailored therapeutics, 
or personalized medicine. Part of this movement means an increase in companion 
diagnostics—the tests that are used to determine whether a particular therapy 
may work for a patient. To address this issue, FDA issued the draft guidance In Vitro 
Companion Diagnostic Devices on July 12, 2011, to communicate to industry how FDA 
defines these devices and what the Agency’s regulatory requirements are for them. 
FDA hopes that by clarifying these topics for industry, we can streamline the process 
to approve companion diagnostics that accurately steer patients toward targeted 
therapies so the right patients receive the right drug at the right dose.
2
Stimulate Innovation in Clinical Evaluations 
& Personalized Medicine to Improve Product 
Development and Patient Outcomes
2
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physiologic, imaging, or genomic endpoints 
in addition to traditional lab tests. Efforts 
to assure the accuracy and consistency of 
analytical measurements while reducing inter-
platform and inter-site variability are critical.
Stimulating innovation in the clinical 
development and evaluation of products 
requires multiple stakeholders. Addressing 
challenges in the early phases of drug 
and biologics discovery, for example, falls 
within the purview of companies and the 
biomedical research community. FDA’s 
regulatory scientists, because of their broad 
and cumulative experience evaluating 
FDA-regulated product submissions, have 
a unique ability to facilitate development 
of knowledge and clinical evaluation tools 
needed for successful translation of discoveries 
into viable products.3, 4 Because the scale of 
data and effort needed to develop, validate 
or qualify clinical evaluation tools is 
enormous, intramural efforts are and should 
be supplemented by collaborative projects 
involving an array of external partners 
including academia, industry, and global 
regulatory agencies.
Implementation Strategy 
FDA will collaborate with others to help 
develop the new tools and approaches needed 
to catalyze the development of personalized 
medicine and to modernize and advance the 
science and conduct of clinical trials. Areas of 
need include:
1.  Develop and refine clinical trial designs, 
endpoints and analysis methods:
a)  Continue to refine clinical trial design and 
statistical methods of analysis to address 
issues such as missing data, multiple 
endpoints, patient enrichment, and adaptive 
designs; 
b)  Identify and evaluate improved clinical 
endpoints and related biomarkers for 
trials in areas where optimal endpoints 
3.  Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products 
http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm
4.  Advancing Regulatory Science for Public Health 
http://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ucm228131.htm
FDA’s regulatory scientists have 
a unique ability to facilitate 
development of knowledge and 
clinical evaluation tools needed 
for successful translation of 
discoveries into viable products.
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are lacking (e.g., efficacy and safety 
endpoints for osteoarthritis in humans and 
animals, for gene therapy, for ophthalmic 
indications, for tumor vaccines, and for 
stem cell-derived therapies);
c)  Develop novel trial designs and endpoints 
for special needs (e.g., small trials for 
orphan indications, designs and endpoints 
for pediatric trials including neonatal trials);
d)  Continue to refine the use of modeling 
and simulation in clinical trial design to 
enhance the effectiveness of clinical studies;
e)  Work with a broad coalition of partners to 
identify key opportunities for improving the 
conduct and efficiency of clinical trials; and
f)  Continue development and refinement of 
tools and approaches for assessing benefit/risk
2.  Leverage existing and future clinical 
trial data:
 a)  Develop quantitative models and measures 
of disease progression; and
b)  Utilize large, pooled clinical trial datasets 
to identify potential trial endpoints, 
explore differences in specific populations 
and subpopulations (e.g., stage of disease, 
chronic disease states, sex, race and 
ethnicity, pediatrics and other age groups) 
and different subsets of diseases, improve 
understanding of relationships between 
clinical parameters and outcomes, and 
evaluate clinical utility of potential 
biomarkers (see section 5).
3.  Identify and qualify biomarkers and study 
endpoints:
a)  Facilitate identification and qualification 
of new and improved biomarkers for safety 
and efficacy, pharmacodynamic response-
dose selection, disease severity, progression 
and prognosis, and pharmacogenomics (to 
predict safety and efficacy or guide dosing);
b)  Develop and evaluate novel approaches for 
biomarker identification, including ‘omics, 
systems biology, and high throughput 
methods; and
c)  Monitor new developments in personalized 
medicine as they pertain to regulated 
medical products.
4.  Increase the accuracy and consistency, and 
reduce inter-platform variability of analytical 
methods to measure biomarkers:
a)  Reduce inter-platform variability of 
analytical methods to measure biomarkers 
through identification of standards and 
FDA will collaborate 
with others to help 
develop the new 
tools and approaches 
needed to catalyze 
the development of 
personalized medicine.
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standardized characterization;
b)  Develop evidentiary requirements to 
demonstrate accuracy and reliability of 
devices that measure biomarkers using 
novel or innovative technologies (e.g., 
whole genome sequencing, new proteomics 
approaches, image analysis);
c)  Promote and develop scientific tools 
to better characterize and standardize 
measurements which have relied on 
subjective reading (e.g., computer-assisted 
diagnostics in imaging, digital pathology 
devices); and
d)  Continue participation in collaborative 
efforts, such as the MicroArray Quality 
Control Consortium, to evaluate the 
quality of validation strategies for emerging 
technologies.
5.  Develop a virtual physiologic patient:
a)  Encourage the development of computer 
models that incorporate radiological 
imaging data of healthy and diseased 
anatomy from a range of relevant diseases;
b)  Ensure the integration of these models 
with genomic and other physiological 
data to promote development of complete 
physiological models and simulations that 
can be used in the development and testing 
of medical devices and other medical 
products; and
c)  Create a library of models so that models 
validated by FDA are easily accessible to 
researchers.
Public Health Impact
The public health impact includes the 
following:
•  Facilitate translation of the huge investment 
in basic sciences by optimizing product 
development and improving patient and 
consumer outcomes;
•  Further basic knowledge needed to develop 
human biomarkers of harm from tobacco 
constituents;
•  Maximize individual therapeutic efficacy 
and minimize harm by identifying 
predictors of individual outcomes; and
•  Facilitate drug and device development for 
special populations (such as for children, 
women, and patients with rare or neglected 
diseases) for which safe and effective 
therapies are very much needed.
Facilitating drug and 
device development 
for special populations 
for which safe and 
effective therapies are 
very much needed.
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Application of novel science and technologies 
is leading both to innovation in manufacturing 
and to innovative products that are often 
complex. In order to foster these innovations, 
FDA needs to do research—collaborating 
with industry and academia —to assess how 
these new technologies affect product safety, 
efficacy, and quality, and to use the information 
to inform development of regulatory policy 
relevant to these innovations. 
In addition, analytical technologies are 
rapidly changing and leading to dramatic 
improvements in sensitivity, resolution, and 
precision in the determination of product 
structure and the detection of contaminants.
Implementation Strategy 
FDA will support the application of novel 
technologies to product development 
and innovative analytical approaches to 
improve product manufacturing and quality 
through active research intramurally and 
collaboratively with external partners by 
addressing each of the following needs:
1.  Enable development and evaluation of novel 
and improved manufacturing methods:
 a)  Investigate the effects of continuous 
manufacturing (manufacturing using a 
continuous process, rather than a batch 
approach) on product quality;
b)  Examine specific novel manufacturing 
technologies to determine how they impact 
product failure rates;
c)  Evaluate the role of excipient ingredients 
and complex dosage forms on product 
safety, efficacy, and quality; and
Support New Approaches to Improve 
Product Manufacturing and Quality3
Quality by Design
Quality by Design is understanding the manufacturing process and identifying the key 
steps for obtaining and assuring a pre-defined final product quality. FDA is constantly 
working to identify ways to improve the manufacturing process to ensure consistent 
product quality throughout the shelf life as well as to identify when contamination or 
other production failures may occur. Improved quality by design will also lower product 
development and manufacturing costs by reducing the likelihood of production failures 
during a long run and by providing opportunities for continuous improvement. As 
part of its Quality by Design effort, FDA is now working on three new areas to support 
increased manufacturing quality. The first is a continuous processing where materials 
constantly flow in and out of equipment. The second is the use of process analytical 
technology to monitor and control processes, as opposed to the current method of just 
testing products. The third is the development of new statistical approaches to detect 
changes in process or product quality.
3
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Application of 
novel science and 
technologies is leading 
both to innovation in 
manufacturing and to 
innovative products that 
are often complex.
d)  Promote two state-of-the-art manufacturing 
strategies—Process Analytical Technology, 
and Quality-By-Design approaches—
for impact on manufacturers’ ability to 
maintain consistent quality.
2. Develop new analytical methods:
a)  Investigate feasibility and value of using 
emerging and improved analytical 
technologies like Nuclear Magnetic 
Resonance (NMR), mass spectrometry, 
or near infrared or Raman spectroscopy 
for evaluating product quality of 
pharmaceutical agents, and evaluate 
whether these technologies should replace 
existing methods;
b)  Evaluate applicability of various analytic 
technologies for determination of the 
“similarity” of biosimilars to their reference 
products;
c)  Perform statistical research to support 
development and evaluation of new assays 
and tests needed to assure analytical 
methods give consistent reproducible 
results; and
d)  Develop improved methods and tools 
to detect and measure the physical 
structure, chemical properties, and safety 
of engineered nanomaterials and complex 
dosage forms (e.g., transdermal patches, 
inhalation delivery systems, and targeted 
drug delivery systems) in FDA-regulated 
products.
3.  Reduce risk of microbial contamination 
of products:
a)  Develop sensitive, rapid, high-throughput 
methods to detect, identify, and enumerate 
microbial contaminants and validate their 
utility in assessing product sterility;
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We are at a critical moment where advances 
in science are leading toward fundamental 
changes in the way medical treatments and 
diagnostics are being developed and used. 
Groundbreaking discoveries in complex 
chemistry and biosynthesis have the promise 
of yielding new drug candidates, and cutting-
edge electronics, nanotechnology and 
materials science have revolutionized medical 
devices. Emerging fields such as gene therapy, 
cell therapy, tissue engineering, optogenetics, 
high intensity focused ultrasound, and 
information technology are also yielding 
innovative approaches to improve our 
health. These novel and increasingly complex 
approaches to health, foods, and medical 
products present growing challenges to FDA’s 
readiness to evaluate new products. Regulatory 
Nanotechnology
As medical products are being revolutionized by cutting-edge technologies like 
nanotechnology, it is more critical than ever for FDA to fully understand how 
nanomaterials are being used in these products. FDA has established Nanotechnology 
Core Centers to provide critically needed equipment and technical staff to conduct 
product assessment and safety research in support of regulatory decision making. 
These centers will facilitate investigations on the safety of products that use 
nanomaterials, establish methods to assess quality and effectiveness of products 
that use nanomaterials, and identify standards to be incorporated in the preclinical 
safety assessment of products that contain nanomaterials.
4
b)  Develop and evaluate methods for 
microbial inactivation/removal from 
pharmaceutical products that are not 
amenable to conventional methods of 
sterilization;
c)  Evaluate the impact of specific 
manufacturing processes on microbial 
contamination; and
d)  Develop reference materials for use by 
industry and academia to evaluate and 
validate novel methods for detecting 
microbial contamination.
Public Health Impact
Regulatory science research on novel 
manufacturing methods and on the analysis 
of products during and after manufacture 
will facilitate adoption of these methods by 
industry, thus facilitating and lowering the cost 
of manufacturing and improving FDA’s ability 
to rapidly evaluate safety, efficacy, and quality 
of products manufactured by these methods.
Ensure FDA Readiness to Evaluate 
Innovative Emerging Technologies4
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We are at a critical 
moment where advances 
in science are leading 
toward fundamental 
changes in the way 
medical treatments 
and diagnostics will be 
developed and used. 
science must be one step ahead to equip 
FDA with the necessary tools and methods 
to reliably assess the safety and efficacy of 
products derived from these new scientific 
developments, in order to bring the rewards of 
discovery safely forward to benefit patients.
 
Implementation Strategy
FDA will develop necessary expertise and 
infrastructure to evaluate new and emerging 
technologies through active research 
intramurally and collaboratively with external 
partners to address each of the following needs:
1.  Stimulate the development of innovative 
medical products while concurrently 
developing novel assessment tools and 
methodologies:
a)  Implement innovation strategies, such as 
the Center for Devices and Radiological 
Health (CDRH)5 Innovation Initiative , 
to facilitate partnerships that create new 
device development and assessment tools.  
This initiative explores ways to initiate 
first-in-human studies earlier in device 
development, offers an expedited pathway 
for development, assessment, and approval 
of important devices, and encourages early 
conversations with developers to make sure 
their ideas are translated into technologies 
that both help patients and are proven safe 
and effective. Other ongoing initiatives to 
stimulate innovation include the Center for 
Veterinary Medicine’s (CVM) InnoVation 
Exploration Team (IVET) to facilitate 
the discovery of novel approaches and 
innovative products while maintaining 
safety, effectiveness, and quality 
standards; and
b)  Encourage promotion of, and participation 
5.  CDRH Medical Device Innovation Initiative accessible at: 
http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHInnovation/default.htm
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in, research and other efforts to increase 
scientific understanding and help 
facilitate assessment of data needs for 
novel regulated products, including those 
relevant to emerging technologies such as 
nanotechnology.6
2. Develop assessment tools for novel therapies:
a)  Develop new approaches such as in vitro 
and in vivo methods to identify measurable 
characteristics of product safety, quality, 
and potency when evaluating new 
therapeutics (e.g., engineered tissues or 
cell therapy products, including stem cell-
derived products, for clinical application in 
regenerative medicine);
b)  Evaluate and adopt new developments in 
the fields of cell biology, developmental 
biology, and materials science to help us 
better understand the impact of interactions 
between living cells and materials used in 
tissue-engineered medical products, as well 
as the interaction of cellular products with 
microenvironments in the patient;
c)  Develop new ways to evaluate gene 
therapy and antisense therapy products 
developed during this period of fast-paced 
scientific progress; 
d)  Integrate an understanding of product 
quality and safety based on novel genomic, 
proteomic, metabolomic, and other -omic 
technologies;
e)  Explore the role of wireless and information 
Initial areas under 
exploration include 
new brain-computer 
interfaces, initially 
coupled with artificial 
limb technology and 
the use of wireless 
technology in 
healthcare.
6.  FDA Nanotechnology Regulatory Science Research accessible at: 
http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/ucm196697.htm
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technologies in new medical therapies and 
diagnostics; and
f)  Conduct periodic, comprehensive horizon 
scanning to identify emerging technologies.
3.  Assure safe and effective medical innovation:
 a)  Develop robust innovation strategies that 
include reaching out to manufacturers 
in areas of high public health need with 
few existing effective interventions and 
challenging scientific hurdles;
b)  Build upon the clinical research initiatives 
to ensure rapid and reliable testing of 
innovative medical products. This may 
include developing new strategies to detect 
novel interactions and toxicities posed by 
novel material and mechanisms of 
action; and
c)  Help stimulate the development, 
standardization, and validation of new 
techniques to assess safety and effectiveness.
4.  Enhance readiness for new applications of 
information technology:
a)  Enhance the collaboration of 
multidisciplinary scientific expertise within 
the Agency when evaluating emerging 
technology product areas; and
b)  Develop mechanisms to promote cross-
disciplinary regulatory science training 
and research to address scientific gaps and 
challenges posed by novel products. 
Public Health Impact
FDA’s efforts will help foster greater 
predictability in the Agency’s regulatory 
processes, enable innovation, and enhance 
transparency while protecting the public 
health. FDA will be better equipped to 
facilitate the translation of groundbreaking 
new products into effective innovative medical 
products, while still maintaining the high 
safety standards Americans depend on.
FDA will be better equipped 
to facilitate the translation 
of groundbreaking new 
products into effective 
innovative medical products, 
while still maintaining 
the high safety standards 
Americans depend on.
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Harness Diverse Data Through Information 
Sciences to Improve Health Outcomes5
FDA receives a vast amount of information 
from a variety of sources, including 
product submissions, adverse event reports, 
de-identified patient data from health care 
providers, and results from surveys and basic 
scientific research. Successful integration and 
analysis of data from these disparate sources 
would provide knowledge and insight not 
possible from any one source alone. A few of 
the many currently untapped opportunities  
include: monitoring adverse event trends 
and disease outbreaks; combining data 
from multiple clinical trials and postmarket 
studies as well as preclinical data; evaluating 
and comparing effectiveness and safety of 
medical and veterinary products in particular 
sub-populations, including sex/gender and 
race/ethnicity analysis, and ultimately host 
genomics and/or genomic response data; and 
large-scale active surveillance for rare events 
and data- and text-mining for a variety of 
research purposes.7
FDA is in the early stages of constructing 
the Information Technology (IT) 
infrastructure necessary for this type 
of complex data integration, but full 
realization of the enormous potential in 
harnessing these diverse data will require 
extensive improvements to the current FDA 
IT environment, as well as new analytic 
approaches and tools. For example, enhancing 
FDA receives a vast amount 
of information from a variety 
of sources, including product 
submissions, voluntary adverse 
event reports, de-identified data 
from health care providers, and 
results from surveys and basic 
scientific research. 
7.  Additional information on the possibilities of data integration can be found in the  PCAST report to the President on 
Realizing the Full Potential of Health Information Technology to Improve Healthcare for Americans, at 
http://www.whitehouse.gov/sites/default/files/microsites/ostp/pcast-health-it-report.pdf
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FDA’s capability to carry out sophisticated data 
mining activities requires a networking and 
computational infrastructure that can support 
an enormous number of simultaneous queries 
of a large set of indexed data sources.
Within each FDA Center there are ongoing 
activities that illustrate the range of 
possibilities and the potential for benefits 
to public health that would be obtainable. 
Expansion, coordination, and improvement of 
the existing IT infrastructure would enhance 
and augment these ongoing activities.
Implementation Strategy 
FDA will develop agency information sciences 
capability to address the following needs: 
1.  Enhance information technology 
infrastructure development and data mining:
a)  Improve access to large, complex data sets to 
solve problems faster or to allow solutions 
of otherwise intractable problems (e.g., 
multi-dimensional map of Salmonella);
b)  Develop secure IT network environment 
(enclave) for scientific computing and 
collaborative research with internal (FDA) 
and external colleagues;
c)  Improve ability to access high speed 
networking and processing to facilitate 
transfer and application of computational 
functions to large, complex datasets (e.g., 
cloud computing); and
d)  Identify computational approaches for rapid 
search and retrieval.
2.  Develop and apply simulation models for 
product life cycles, risk assessment, and other 
regulatory science uses:
a)  Identify opportunities and develop computer 
simulation and modeling to streamline data 
analysis and model biological systems and 
their responses to agents of concerns, such as 
toxins, pathogens, electromagnetic energy, 
and biomaterials; and
b)  Promote novel clinical trial design using 
simulation, new statistical models, and 
novel animal models/animal model 
alternatives.
3.  Analyze large scale clinical and preclinical 
data sets:
a)  Continue to refine methods for analysis of 
post-market data, including data mining 
of spontaneous reports and analysis of 
electronic health records from accessible 
large healthcare databases;
b)  Continue and expand patient centered 
outcomes research by compiling datasets 
converted to standardized format across 
critical classes of drugs that are entered into 
PACES Initiative
FDA is currently undertaking projects with enormous potential to unlock the data 
from product applications reviewed by FDA. By integrating and analyzing these 
data, FDA will be able to provide industry with new information that can be 
applied to future product development and potentially save billions of dollars in 
development costs. One of the programs is the academic Partnership in Applied 
Comparative Effectiveness Science (PACES) project funded by FDA. PACES facilitates 
pilot projects to conduct advanced analyses to detect clinical trends to determine 
which interventions will be most effective for which patients under which specific 
conditions. This will cut out many of the headaches of trial-and-error to find the right 
treatment for a particular patient.
5
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the clinical trials repository and Janus;8 and
c)  Provide FDA access to data from a variety of 
large patient databases, including Sentinel9 
where FDA is working with multiple 
partners within government and the private 
sector. Mini-Sentinel project is an active 
prototype of the full system.
4.  Incorporate knowledge from FDA regulatory 
files into a database integrating a broad 
array of data types to facilitate development 
of predictive toxicology models and model 
validation (Also see: Section 1)
5.  Develop new data sources and innovative 
analytical methods and approaches:
a)  Lead the development of scientific 
infrastructure for national and international 
registries to advance the regulatory 
science and surveillance of medical 
products throughout their lifecycle (e.g., 
International Consortium of Orthopedic 
Registries - ICOR); and
b)  Advance development of innovative 
methodological approaches, such as 
evidence generation, synthesis, and 
evaluation throughout device life cycle 
through the Medical Device Epidemiology 
Network (MDEpiNet) Initiative.
Public Health Impact
Expansion and improvement of the existing 
FDA IT infrastructure and application of IT 
resources to support sophisticated analyses 
of data will have a number of positive 
impacts. Access to this data would provide 
the ability to better predict failure or better 
design future drugs, future and existing 
devices, and additional studies. This would 
increase the efficiency and effectiveness 
of new products and studies, potentially 
resulting in better products getting to 
patients faster. Development and testing of 
novel methodologies for the synthesis and 
systematic evaluation of all available evidence 
will allow comprehensive, up-to-date risk-
benefit balance determination at any point of 
the product life cycle so that FDA can make 
optimally informed decisions and provide 
more useful information to practitioners, 
patients, and industry. 
8.  Janus is an enterprise initiative to improve FDA’s management of structured scientific data about regulated 
products in support of regulatory decision-making. For more information, please go to http://www.fda.gov/downloads/
AdvisoryCommittees/CommitteesMeetingMaterials/ScienceBoardtotheFoodandDrugAdministration/UCM224277.pdf
9.  Sentinel is a national electronic system that will transform FDA’s ability to track the safety of drugs, biologics, medical 
devices, and ultimately all FDA-regulated products once they reach the market.  For more information, please go to 
http://www.fda.gov/Safety/FDAsSentinelInitiative/ucm2007250.htm
Expansion and 
improvement of the 
existing IT infrastructure 
would enhance and 
augment these ongoing 
activities.
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The recently enacted Food Safety 
Modernization Act (FSMA), the first major 
overhaul of our food safety law in over 
70 years, will transform FDA’s food safety 
program by providing it with new public 
health mandates and enhanced tools for 
ensuring the safety of the food supply in the 
21st Century. FSMA emphasizes the concept 
of preventing problems before they occur and 
provides new tools to require manufacturers 
to implement prevention plans. Additionally, 
FSMA requires FDA to respond quickly and 
effectively when problems do occur.
Implementation Strategy 
FSMA mandates a new approach to FDA’s 
current food safety system, emphasizing 
prevention and risk-based priority setting and 
resource allocation to address the challenges 
of the modern food safety environment. 
Although prevention is paramount, enhanced 
response and investigation efforts to 
foodborne outbreaks when they occur is also 
critical. To effectively implement this new 
food safety mandate, it is imperative that FDA 
ensures a strong science infrastructure, clearly 
identifies its research needs, and collaborates 
with other public health and research agencies 
in the Federal government, state government 
agencies, academia, and private industry. 
Specifically, FDA will focus on the following: 
1.  Establish and implement centralized planning 
and performance measurement processes:
a)  Establish and implement Foods Program 
science/research strategic planning and 
operational planning processes;
b)  Develop mechanisms to identify and 
prioritize research needs critical to 
achieving the Agency’s public health and 
consumer protection goals;
c)  Harmonize microbiological and chemical 
analytical methods development and 
validation across the Foods Program to 
FSMA mandates a new 
approach to FDA’s current 
food safety system, 
emphasizing prevention and 
risk-based priority setting and 
resource allocation to address 
the challenges of the modern 
food safety environment.
Implement a New Prevention-Focused Food 
Safety System to Protect Public Health6
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Food Pathogens
As a regulatory agency tasked to ensure the safety of the nation’s food supply, it 
is imperative that the analytical methods our laboratories employ for surveillance, 
compliance, and outbreak investigations meet the highest standards of performance. 
FDA is meeting this challenge through the development of performance standards 
for all methods to detect microbial pathogens and chemical and radiological 
contaminants, and to harmonize method validation guidelines for all methods 
developed and used in our testing laboratories. Currently, guidelines to govern 
analytical methods designed to detect food-borne microbial pathogens are nearing 
completion and will cover methods for the detection of food-borne bacterial 
pathogens (e.g., Salmonella, Listeria, and Shigella) viruses (e.g., Hepatitis A virus, 
Norovirus) and other pathogens (e.g., Cyclospora and Cryptosporidium). These 
guidelines will also address performance evaluation criteria (verification and 
validation) necessary for the use of commercially-available microbiological diagnostic 
kits and platforms in FDA regulatory laboratories. At the same time, FDA is also 
actively collaborating with other government agencies, international partners, and 
multiple accrediting bodies to achieve a similar consensus on method performance 
standards and validation criteria. As collaborative global food safety surveillance 
programs increase, harmonization of standards and validation criteria will allow 
for greater data sharing and data acceptance between the US and our international 
trading partners.
6
As collaborative global food 
safety surveillance programs 
increase, harmonization of 
standards and validation 
criteria will allow for greater 
data sharing and data 
acceptance between the 
US and our international 
trading partners.
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enhance detection and removal of unsafe 
contaminants from the Nation’s food and 
feed supply; and
d)  Plan and implement ongoing collaborative 
activities between science and research 
elements of programs and Centers and 
Federal and State partners where appropriate.
2.  Improve information sharing internally and 
externally:
a)  Effectively communicate research plans and 
results within the Foods Program to Federal 
and State partners, the public, and other 
interested stakeholders;
b)  Develop centralized IT infrastructure to 
collect, analyze, and share foods science/
research data with program offices;
c)  Evaluate the impact of publications 
and presentations on the scientific and 
regulatory community; and
d)  Improve communication with food 
importers to provide rapid notification of 
negative test results
3.  Maintain mission critical science capabilities:
a)  Identify and invest in disciplines and 
specialties that are critical to carrying out 
the Foods Program mission;
b)  Identify and invest in emerging disciplines, 
sciences, and technologies to mitigate future 
risks in food safety (Also see: Section 4); and
c)  Maintain and enhance the science/
technology infrastructure to support 
day-to-day operations. This will ensure 
the infrastructure exists at FDA to 
promptly recognize, evaluate, and ensure 
effective controls for food and feed safety 
hazards (microbiological, chemical, and 
radiological).
4. Cultivate expert institutional knowledge:
a)  Develop integrated Foods Program training 
requirements and training program for 
cross-functional scientific staff.
Public Health Impact
An integrated science/research program 
based on the principles of prevention and 
risk-based priority setting provides research 
solutions to support current and evolving 
FDA regulatory issues and is critical to meet 
FDA regulatory science priorities outlined in 
this initiative. The investment in this public 
health focus will strengthen FDA’s ability to 
prevent the occurrence of future food and 
feed safety contamination events, and if 
necessary, quickly respond to microbial and 
chemical contamination events. This initiative 
will also allow for greater collaboration and 
coordination between operating divisions 
under the umbrella of the Office of Foods 
(i.e., CFSAN and CVM) and components of 
ORA and NCTR, and will enable FDA to meet 
emerging challenges in the food safety arena.
The investment in this 
public health focus will 
strengthen FDA’s ability to 
prevent the occurrence of 
future food and feed safety 
contamination events.
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Medical countermeasures, or MCMs, are 
drugs, biologics (including vaccines), devices 
(including diagnostic tests and personal 
protective equipment), and other equipment 
and supplies for response to public health 
emergencies involving chemical, biological, 
radiological, or nuclear (CBRN) threat agents 
or naturally-occurring infectious disease 
outbreaks. The range of MCMs required to 
rapidly and effectively respond to these types 
of public health emergencies is not yet fully 
developed. Moreover, there is limited capability 
to rapidly develop a new MCM in response to 
a new or emerging threat, and only limited 
capacity to ramp up production of existing 
MCMs once an event is detected. 
An extensive review of the U.S. processes and 
infrastructure for developing, approving, 
and stockpiling MCMs, released in August 
2010, identified FDA as one of the most 
critical components of the nation’s Public 
Health Emergency Medical Countermeasures 
Enterprise (PHEMCE). Because FDA is 
responsible for evaluating product safety 
and efficacy, it has significant understanding 
of the steps required for successful product 
development. Harnessing FDA knowledge 
and expertise in the form of a comprehensive 
MCM initiative will help establish regulatory 
pathways based on the most advanced 
scientific foundations available, accelerate 
MCM development, and realize the promise of 
new technologies for faster development and 
flexible, rapidly scalable manufacture of MCMs.
To attain these goals, in 2010, FDA launched 
the Medical Countermeasures initiative 
(MCMi) which consists of three pillars to 
establish regulatory pathways and accelerate 
MCM development toward approval: 1) 
enhancing the regulatory review processes 
for MCMs; 2) advancing regulatory science 
for MCM development and evaluation; and 
Facilitate Development of Medical 
Countermeasures to Protect Against Threats 
to U.S. and Global Health and Security
7
Medical countermeasures, 
or MCMs, are drugs, 
biologics devices, and other 
equipment and supplies for 
response to public health 
emergencies.
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3) modernizing the legal, regulatory, and 
policy framework for effective public health 
response. The second pillar, advancing 
regulatory science, is critical for realizing 
the promise of multiyear investments by the 
nation to develop MCMs, since development 
of many MCMs is impeded by the lack of 
key scientific information, animal models, 
or methods needed to assess their safety or 
efficacy. In particular, when efficacy studies 
in humans are unethical or infeasible, studies 
in animal models10 will typically be needed to 
provide the efficacy data required to support 
approval, licensure, clearance, or emergency 
authorization. Alternatively, in those cases 
where no freshly collected human specimens 
are available for development and validation 
of diagnostic assays, well-characterized 
archived specimens or, in some instances, even 
contrived or simulated specimens, may be 
used to assess assay performance. To facilitate 
development of safe and effective MCMs 
against diseases or conditions caused by CBRN 
threats or emerging infectious diseases,11 FDA 
will work closely with the federal government’s 
PHEMCE partners, as well as academia and 
industry, to focus its scientific agenda on four 
overarching areas: develop, characterize and 
qualify animal models for MCM development; 
modernize tools to evaluate MCM product 
safety, efficacy, and quality; develop and 
qualify biomarkers of diseases or conditions; 
and enhance emergency communication. 
In addition, FDA will conduct product 
needs assessment in collaboration with the 
clinical community, academia, industry, 
and Biomedical Advanced Research and 
Development Authority (BARDA) to identify 
products that can be delivered efficiently and 
applied easily without requiring advanced skill 
or expertise, and furthermore have potential 
for broadest impact.
Implementation Strategy 
In close alignment with priorities identified by 
the PHEMCE, FDA will facilitate development 
of safe and effective MCMs through both 
intramural research and collaboration 
with external partners (e.g., academia, U.S. 
government agencies, non-governmental 
10.  For more on requirements for approval or licensure under these conditions see “The Animal Rule: New Drug and 
Biological Drug Products; Evidence Needed to Demonstrate Effectiveness of New Drugs When Human Efficacy 
Studies Are Not Ethical or Feasible; Final Rule,” 5/31/2002.
11. For the purpose of this paper, “threat agent” will include CBRN threats as well as emerging infectious diseases.
FDA will facilitate 
development of safe and 
effective MCMs through 
both intramural research 
and collaboration with 
external partners.
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organizations, and industry) to address, for 
example, the following needs:
1.  Develop, characterize, and qualify animal 
models for MCM development: 
a)  Develop and evaluate animal models for 
the ability to demonstrate a response to the 
countermeasure that will be predictive for 
humans, including the ability to extrapolate  
pharmacokinetic/pharmacodynamic (PK/PD) 
data from animals to humans to determine 
appropriate dosing in humans; and
b)  Develop a database of non-clinical 
efficacy models to support development 
of biomarkers and endpoints, and inform 
decision-making on feasibility of certain 
animal models to support approval or 
licensure of MCMs (Also see: Section 1).
2.  Modernize tools to evaluate MCM product 
safety, efficacy, and quality:
a)  Partner with the Department of Health and 
Human Services (HHS) and Department 
of Defense (DOD) to support and facilitate 
development of advanced manufacturing 
approaches and facilities, including rapid, 
scalable, platform approaches;
b)  Identify and evaluate methods to improve 
availability and reuse of personal protective 
equipment;
c)  Continue to develop electronic data 
standards and report forms to facilitate 
rapid assessment of the safety and efficacy of 
deployed MCMs;
d)  Develop reference materials related 
to relevant threat agents to facilitate 
development of preventive vaccines, 
therapeutics, and detection and diagnostic 
methods; and
e)  Develop and evaluate high throughput, 
sensitive, specific, cost-effective methods to 
detect threat agents, diagnose the disease 
or condition, and perform broad-based 
pathogen detection.
3.  Develop and qualify biomarkers of diseases or 
conditions:
a)  Improve knowledge of natural history of 
Vaccines
Each year, the influenza vaccine is slightly different due to accumulated genetic 
changes in circulating influenza viruses. In order to develop a protective vaccine, 
the strain for the vaccine needs to be matched to the expected strains circulating. 
Once produced, the manufacturer needs to be able to accurately measure the 
potency of each strain component in the vaccine, which requires the production of 
reagent standards, including a strain-specific antiserum. This is typically done by 
purifying the hemagglutinin (HA) protein from the flu vaccine strain, immunizing 
sheep with the purified protein, and then using the resulting antisera to analyze the 
manufactured vaccine. HA purification is time-consuming and often unsuccessful, 
and can become a rate-limiting step in the final lot release testing on the vaccine 
strain if the antisera are not available. CBER scientists have shown that they can use 
recombinant DNA techniques to generate the HA protein in the absence of a virus as 
an alternative method for preparation of pandemic influenza strain-specific antibody 
for vaccine potency determination. The resulting antisera from sheep immunized 
with the recombinant HA have shown identical sensitivity and specificity to those 
sera obtain from HA purified from the virus.
7
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pathophysiology of human diseases or 
conditions caused by CBRN agents;
b)  Identify and develop biomarkers that 
enhance the understanding of the 
mechanism of action of MCMs, and 
may provide measures of MCM product 
efficacy; and
c)  Determine pathogenesis in relevant 
nonclinical models and evaluate for 
predictive value to human condition.
4. Enhance emergency communication:
a)  Evaluate past risk and emergency 
communications to identify and improve 
the effectiveness of communications in a 
public health emergency;
b)  Improve quality and health literacy level of 
FDA communication about FDA-regulated 
products; and
c)  Enhance FDA’s capabilities and develop 
new strategies to collect, monitor, and 
track during emergencies real time data on 
adverse events associated with the use of 
drug, biologic, and device MCMs.
Public Health Impact
Advancing regulatory science in the areas 
above will provide enhanced preparedness 
by establishing more flexible and nimble 
manufacturing processes and by creating data, 
tools, and methods to speed development and 
evaluation of MCM product safety, efficacy, and 
quality. Improved scientific data will facilitate 
development of safer, more efficacious products 
to respond to threats—should that become 
necessary—thus mitigating the morbidity and 
mortality of an attack or outbreak fostering 
resilience and recovery.
The MCM regulatory science program 
will bring the nation a step closer to the 
preparedness and response capabilities 
articulated in the HHS Public Health 
Emergency Medical Countermeasures 
Enterprise Review, where the nation’s MCM 
Enterprise is equipped to respond to any attack 
or threat, known or unknown. 
Ultimately, the output of MCM regulatory 
science will have substantial implications 
for improving the health and security of the 
U.S. population beyond CBRN and emerging 
infectious disease threats. Advancing regulatory 
science to support development of MCMs 
will contribute directly and indirectly to 
development of safer, better products for other 
diseases and conditions.
Advancing regulatory science 
to support development 
of MCMs will contribute 
directly and indirectly to 
development of safer, better 
products for other diseases 
and conditions.
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Strengthen Social and Behavioral Science 
to Help Consumers and Professionals Make 
Informed Decisions about Regulated Products
8
One way that FDA protects the public from 
harm and promotes public health is by ensuring 
easy public access to sound information.12 This 
is accomplished by setting and enforcing high 
standards for product information and quality 
to ensure that labels are accurate, products truly 
are what their labels claim, and advertising 
about these products is clear, truthful, and in 
no way misleading. FDA also seeks to provide 
clear information about how to use products to 
promote health or reduce harm so consumers 
and health professionals can make informed 
decisions, and FDA communicates new or 
emerging situations so Americans have up-to-
date information about products on the market. 
To enhance the utility of information 
provided to the public, FDA needs a science-
based approach for developing an effective 
communication strategy, including developing 
messages, testing how the public understands 
information, assuring optimal delivery to 
relevant populations, and assessing the impact 
of the information on public understanding, 
attitudes, and behaviors. A major challenge 
is adapting FDA’s communications to rapidly 
evolving technologies that are driving major 
shifts in how consumers choose to receive and 
share information.
Implementation Strategy 
To facilitate the translation of science-based 
regulatory decisions and information into 
public health gains, FDA must strengthen 
social and behavioral sciences in the areas 
of understanding and reaching diverse 
audiences, ensuring audience comprehension, 
and evaluating the effectiveness of 
communications in changing behaviors related 
to the use of regulated products. FDA scientists 
are working internally or collaboratively to 
address the following needs:
 
1. Know the audience:
a)  Improve understanding of how the 
multitude of factors related to the individual 
(e.g., age, sex, race/ethnicity, zliteracy, 
motivation, skills) and the information 
FDA needs a science-
based approach for 
developing an effective 
communication strategy.
12. Hamburg MA, Sharfstein JM.  The FDA as a Public Health Agency.  N Engl J Med 2009 Jun 11;360(24):2493-5
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Tobacco Regulation
Under the Family Smoking Prevention and Tobacco Control Act (P.L. No: 111-31), FDA 
is responsible for the regulation of the manufacture, distribution, and marketing of 
tobacco products. Following an experimental study that tested 18,000 adult smokers 
and susceptible youth on the relative effectiveness of various graphic health warnings, 
in June 2011 FDA launched new graphic health warning labels for cigarettes, marking a 
significant advance in communicating the dangers of smoking. These new labels mark 
the first change in cigarette warnings in more than twenty-five years. The nine new 
labels warn of risks such as addiction, cancer, and lung disease, and will be required 
on all new cigarette packages beginning September 2012.
provided on or with products (e.g., wording, 
placement, required vs. voluntary) impact 
decision makers’ responses to product, 
label, and agency-provided information.
2. Reach the audience:
a)  Improve understanding of information 
channels and identify the most effective 
methods of delivering information to an 
intended audience, including audiences 
with diverse backgrounds; 
b)  Identify the most effective methods to 
inform tobacco retailers about FDA’s 
regulatory and enforcement authorities; and
c)  Expand understanding of how online media 
promote and advertise FDA-regulated 
products.
3. Ensure audience understanding:
a)  Enhance understanding of how message 
format and content affect consumers’ 
and health professionals’ attitudes about 
regulated products;
b)  Assess how consumer perceptions of risks 
associated with FDA-regulated products are 
affected by product claims;
c)  Improve methods to convey complex 
scientific and quantitative information 
about product risks and benefits (e.g., 
quantitative risk information, clinical trial 
results, toxicology data) to consumers and 
professionals; and
d)  Understand how exposure to non-target 
messages (e.g., promotional offers, 
distractions in TV ads) affects consumers’ 
understanding of product information.
4. Evaluate the effectiveness of communication 
about regulated products:
a)  Develop methods to identify and track 
public understanding, perceptions, 
and attitudes towards product-related 
information;
b)  Describe the impact of format and content 
on behaviors related to product use or 
misuse, including prescribing practices;
c)  Develop methods to rapidly assess public 
understanding and attitudes about recalls 
and other time-sensitive FDA messages to 
make timely adjustments to the information 
and/or channels when appropriate; and
d)  Determine the impact of FDA-regulated 
direct-to-consumer advertising on reporting 
of adverse events associated with product use.
Public Health Impact:
Strengthening social and behavioral sciences 
will allow FDA to better equip American 
consumers and health professionals with 
the information they need to make sound 
decisions about using, prescribing and 
dispensing products. This has the potential to 
decrease preventable adverse events related to 
FDA-regulated products. 
8
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Importance of a 
Strong Regulatory 
Science Culture 
and Infrastructure
Implementation Strategies for the Strategic Plan 
for Regulatory Science
By identifying key scientific challenges 
and implementation plans within each 
priority area, FDA is providing a guide for its 
regulatory science efforts and a focal point 
for research and development activities 
beyond the walls of the Agency. It should 
be noted that while FDA is a science-based 
agency that does and will continue to directly 
support regulatory science research, it is not 
primarily a funding agency. FDA is, however, 
an agency that has scientific staff spanning 
diverse disciplines from food science to 
engineering to medicine, who are making 
important contributions to the biomedical, 
tobacco, toxicology, and foods science research 
enterprises. The sections below briefly describe 
some of the potential avenues for fostering a 
strong regulatory science culture, improving 
the scientific infrastructure, and promoting 
and engaging in the regulatory science 
research agenda laid out in this plan.
Partnerships with Government Agencies
Currently FDA is actively collaborating with 
several government agencies and departments 
to provide guidance, co-sponsor, collaborate, 
or partner to promote regulatory science 
programs. These relationships include the 
formation of an NIH-FDA leadership council, 
which launched its first Regulatory Science 
Requests for Applications (RFA) under 
which four regulatory research programs 
T
his report has outlined a number of priority areas where FDA believes 
advances in the underlying regulatory science will catalyze innovation 
in regulatory review as well as product and methods development. 
Each scientific emphasis area presented in this plan represents 
opportunities to drive a new and important research agenda using 
a variety of means, from enhancing the FDA internal research program to 
participation in consortium models.
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are currently being supported, as well as 
ongoing and active participation in the design, 
development and approval of projects that are 
part of the NIH Biomarkers Consortium.  
FDA is continuing to explore expansion 
of efforts with NIH as well as new efforts 
with other agencies to promote and support 
regulatory science research and development.  
A critical component of the FDA science 
strategic plan will be implemented through 
enhanced collaborations between FDA and 
other agencies, both to leverage funding for 
supporting outside research but as importantly 
to establish new, collaborative, intramural 
research projects where expertise from each 
agency can be brought to bear on regulatory 
science research projects.
Staff Scientific Training and 
Professional Development
In addition to the proactive regulatory science 
efforts outlined in this plan, it is essential 
to maintain the capacity and in-house 
scientific and technical expertise needed 
both to evaluate increasingly complex and 
innovative products and technologies and 
to respond rapidly and effectively to public 
health emergencies. A strong in-house science 
base and a network of collaborations is 
necessary to help support FDA’s success in 
addressing these public health challenges, 
and FDA is supporting various mechanisms 
where staff have opportunities to increase 
their knowledge and skills, thereby 
strengthening the Agency’s science base. FDA 
staff training and professional development 
is enhanced by participation in scientific 
and professional meetings and conferences 
where experts present their most current 
research and through collaborations and 
relationships, both formal and informal, 
with academic institutions that provide FDA 
with access to cutting edge science through 
courses, workshops, and seminars. Academic 
collaborations also support faculty coming to 
FDA to impart their knowledge, in addition 
to FDA staff participating in academic 
activities and initiatives to bring knowledge 
back to the Agency. Additionally, every year 
the Commissioner’s Fellowship Program 
brings talented young scientists with cutting 
edge experience in academia, industry, and 
government to FDA every year to work with 
FDA scientists and learn about regulatory 
science and review. 
Direct Funding Mechanisms
The FDA product Centers and Offices, such 
as the Office of Critical Path Programs 
within the Office of the Commissioner are 
currently engaged in direct support of relevant 
scientific programs in the form of grants, 
cooperative agreements, or contracts. These 
programs supply both research support and 
in many cases collaborative engagement 
with and guidance from scientists across the 
Agency. Recent examples include RFAs to 
fund cooperative agreements for regulatory 
science programs in the areas of reproductive 
toxicology and biomarker qualification, 
and for a pilot program to potentially 
support a regional academic collaboration 
with a Center for Excellence in Regulatory 
Science and Innovation (CERSI) to support 
regulatory science research, training, scientific 
exchanges, and professional development. 
Moving forward, FDA will continue to engage 
A critical component of the FDA science strategic 
plan will be implemented through enhanced 
collaborations between FDA and other agencies.
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selectively in direct funding mechanisms to 
seed important areas of science noted in this 
strategic plan. FDA’s limited funds, however, 
will generally need to be targeted for initial 
pilots or start up funds that will be used to 
leverage resources from other sources, such as 
other government agencies, industry through 
consortium models, or philanthropy. FDA will 
continue to identify key areas for investments 
through issuance of competitive solicitations 
and will work to partner, in particular with 
the NIH, to directly support as much of the 
regulatory science agenda as feasible.
Public-Private Partnerships
Public-Private Partnership (PPP) models 
are a key component of the implementation 
strategy for FDA regulatory science. PPPs are 
one mechanism that can be used to leverage 
FDA resources by working collaboratively with 
both public and private partners, to achieve our 
mission as well as that of the partners. PPPs 
may take many forms and can range widely 
in size and scope. In addition, PPPs provide 
a means to leverage funds from academic 
institutions, FDA, other government agencies, 
and industry to support regulatory science 
priority areas as defined in this plan.
FDA can collaborate with partners from a 
wide range of other organizations including, 
but not limited to, patient advocacy groups, 
professional societies, charitable foundations, 
industry members, trade organizations, 
and academic institutions. FDA PPPs can 
be designed around the strategic priorities 
set forth herein and constructed in ways 
that advance the regulatory science research 
efforts of FDA in an efficient and cost-
effective manner. Because these partnerships 
will be science-driven, aimed at advancing 
regulatory science, and structured to uphold 
the principles of transparency, fairness, 
inclusiveness, scientific rigor, and compliance 
with Federal laws and FDA policy, they are 
a valuable tool to achieving the Agency’s 
mission of advancing regulatory science. 
Currently FDA is engaged in several PPPs 
including the Clinical Trials Transformation 
Initiative and MDEpiNet Initiative.
One unique vehicle for establishment of PPPs 
is the Reagan-Udall Foundation (RUF), a non-
profit foundation established by Congress for the 
purpose of advancing the regulatory science that 
FDA needs to accomplish its mission. RUF was 
designed to be a vehicle for bringing an array 
of resources and perspectives to bear on high 
priority FDA regulatory science projects. RUF 
can create consortia of patient groups, industry, 
academia, and FDA scientists to design and 
implement regulatory science research.
FDA can collaborate with partners from a 
wide range of other organizations including, 
but not limited to, patient advocacy groups, 
professional societies, charitable foundations, 
industry members, trade organizations, and 
academic institutions.
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Moving Forward
The headlines are replete with examples of 
the critical scientific role the Agency plays 
in addressing crises, such as contaminated 
heparin, melamine in pet food, outbreaks 
of food-borne illness, and questions about 
vaccine safety, seafood safety, or readiness 
for pandemic influenza. A strong FDA 
science infrastructure provides the essential 
foundation for ensuring scientific excellence 
and integrity in all of our regulatory and 
public health decisions and activities. 
Successful engagement of other scientific 
communities in academia, industry, and 
government will be essential to attainment 
of FDA goals. FDA scientists must work in an 
environment that fosters creative thinking, 
promotes scientific multidisciplinary 
interaction and collaboration, offers 
opportunities for learning, ensures both 
scientific excellence and integrity, and 
provides access to state-of-the-art laboratory 
and computer technologies. The Agency will 
develop creative ways to use technology 
to expand opportunities for training and 
collaboration, leverage external expertise 
and infrastructure through collaborative 
mechanisms to broaden the range of research 
possibilities, and provide joint training 
opportunities with external partners. It will 
also maximize the impact of regulatory 
science investments by publishing in peer-
reviewed scientific and medical journals and 
communicating research findings to the public 
by using Internet tools, such as its existing web 
site at www.fda.gov as well as some of the newer 
Web 2.0 tools available, to the maximum 
extent possible. In addition, to ensure the 
regulatory science remains up to date, FDA 
will periodically use the FDA Science Board 
and other outside scientific expertise to aid in 
identifying and prioritizing research efforts 
and to provide input on the relevance, quality, 
and productivity of the Agency’s regulatory 
science programs. A successful regulatory 
science program will translate key findings 
into FDA guidance and communications, 
both informal and formal, that reflect the 
latest scientific understanding as it relates to 
regulatory policy and decision making. 
Conclusion
Advances in science and technology are moving forward rapidly and have created 
unprecedented challenges and opportunities in U.S. and global health. FDA plays a 
critical role in protecting and promoting the nation’s health and regulates industries 
that are among the most successful and innovative in the world. Critical responsibilities 
across the products FDA regulates require application of the best available science to 
keep pace with these advances and make decisions and take actions that both support 
innovation and protect and promote the public health.
The FDA Strategic Plan for Regulatory Science identifies critical priority areas and 
activities where new or enhanced engagement in regulatory science research is essential 
to continued mission success. Successful implementation of this regulatory science 
plan, including engagement with diverse stakeholders, will allow the Agency to fulfill its 
regulatory mission today while also being prepared for the new challenges of tomorrow.
Glossary
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